Beijing Foyou Pharma Co., Ltd. Class A

Beijing Foyou Pharma Co., Ltd. Class A

SSSE:601089
14.83
CNY
-0.18
(-1.20%)
0.79EPS
21.07P/E
7.91BMarket Cap
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
5.85
6.76
7.05
7.85
7.68
6.97
7.33
7.47
7.67
Basic EPS, GAAP
0.58
0.61
0.73
0.87
1.04
1.02
1.04
1
0.78
Free Cash Flow per Basic Share
0.53
0.6
0.6
0.93
1.24
0.4
0.64
-0.08
- -
Dividend per Share
0.04
0.2
0.33
0.32
0.26
0.41
0.5
0.5
- -
Book Value per Share
1.91
2.36
2.79
3.37
6.61
7.23
7.38
7.87
7.96
Tangible Book Value per Share
1.74
2.19
2.64
2.96
6.32
6.91
7.09
7.58
7.68
Basic Weighted Avg Shares
346
359
360
361
422
479
470
469
470
Sales/Revenue/Turnover
2,020
2,425
2,535
2,838
3,240
3,340
3,446
3,504
3,607
Operating Margin (%)
12.9
10.74
12.7
13.01
14.15
15.27
14.73
14.94
11.12
Depreciation Expense
38
43
44
63
83
98
102
129
- -
Net Income, GAAP
200
219
263
314
439
489
489
469
368
Effective Tax Rate (%)
12.26
10.73
11.77
13.61
9.53
10.35
8.89
9.95
7.66
Profit Margin (%)
9.92
9.02
10.36
11.08
13.55
14.64
14.18
13.39
10.2
Working Capital
273
377
385
413
2,319
2,330
2,011
2,001
2,102
LT Debt
67
36
10
50
62
45
21
9
2
Total Equity
685
848
1,008
1,215
3,179
3,477
3,556
3,793
3,835
Return on Invested Capital (%)
- -
20.2
23.78
24.83
18.2
14.18
13.58
12.82
10.01
Return on Capital (%)
- -
21.42
23.91
25.92
19.01
14.2
13.51
12.59
9.81
Return on Common Equity (%)
- -
28.52
28.35
28.37
20.01
14.72
13.94
12.82
9.95

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
14
11
11
LT Borrowings
- -
- -
- -
LT Finance Leases
6
7
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
480
480
480
Market Capitalization
11,069
7,814
7,910

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
3,078
2,972
3,137
Cash, Cash Equivalents & STI
2,139
2,043
2,143
Accounts Receivable, Net
380
376
401
Inventories
425
426
456
Total Current Liabilities
967
981
1,035
Payables & Accruals
- -
- -
- -
ST Debt
14
11
11
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
40.1%
6.66%
Free Cash Flow
- -
-1.6%
-112.22%
Net Income, GAAP
- -
13.33%
-3.95%
Sales/Revenue/Turnover
- -
6.81%
1.71%
Total Cash Common Dividend
- -
17.74%
-0.99%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
803
853
892
899
3,446
2025
830
803
- -
984
3,504
2026
811
899
913
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.28
0.34
0.24
0.19
1.04
2025
0.27
0.29
- -
0.2
1
2026
0.2
0.19
0.19
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.5
- -
- -
0.5
2025
- -
0.5
- -
- -
0.5
2026
- -
- -
- -
- -
- -

Company Description

CEO
He Huang
Full Time Employees
3,908
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Beijing China
IPO Date
Jun 30, 2022
Business
Beijing Foyou Pharma Co., Ltd., a subsidiary of NHU Holding Group Co., Ltd., is a China-based pharmaceutical and medical technology company engaged in the research, development, manufacturing, and commercialization of chemical generic drugs, active pharmaceutical ingredients (APIs), innovative biopharmaceuticals, and clinical medical devices. Tracing its operational roots to 1999 and incorporated in its current structure in May 2019, the company is headquartered in Beijing, China, and operates multi-site manufacturing and R&D facilities across Beijing, Cangzhou in Hebei Province, Xuancheng in Anhui Province, and Hangzhou in Zhejiang Province. Beijing Foyou Pharma operates an integrated API-to-formulation supply chain, serving hospital networks, clinical care institutions, and retail pharmacies across domestic and international markets. The company's core business is organized into two primary segments: Pharmaceutical Preparations and Medical Devices. The Pharmaceutical Preparations segment provides treatments across several key therapeutic categories: cardiovascular medications, including Telmisartan Tablets sold under the Shuniya brand, Telmisartan-Hydrochlorothiazide Tablets, Olmesartan Medoxomil Tablets and Orally Disintegrating Tablets, Valsartan-Amlodipine tablets, and Clopidogrel-Aspirin Tablets; endocrine and diabetes therapies, including Repaglinide Tablets sold under the Wansheng Liping brand, Epalrestat Tablets, and Saxagliptin-Metformin; chronic kidney disease therapies, including Compound Alpha-Ketoacid Tablets sold under the Keluodi brand; dermatological and topical drugs, including Fluticasone Propionate Creams, specialized glucocorticoid formulations, and functional skin barrier agents; and digestive, neuropsychiatric, respiratory, and gynecological drugs, including Dydrogesterone Tablets, Acetylcysteine Tablets, and selective psychotropic formulations. The Medical Devices segment specializes in clinical nursing, patient monitoring, and respiratory care equipment: medical micro-mesh nebulizers; disposable oxygen delivery masks and nasal cannula systems; digital urine collection systems and intelligent volume monitors; urodynamic monitoring apparatus; and disposable medical pressure transducers. In recent developments, Beijing Foyou Pharma has advanced its strategic transformation toward innovative biomedicine by leveraging its proprietary N-ER oligonucleotide drug delivery platform to advance multiple small interfering RNA (siRNA) therapeutic candidates into Phase I clinical trials for liver-targeted and extrahepatic metabolic indications. Concurrently, the company has expanded its commercial portfolio through National Medical Products Administration (NMPA) regulatory approvals for new generic formulations, including first-to-market approvals for Olmesartan Medoxomil orally disintegrating tablets, Clopidogrel-Aspirin combination tablets, and Dydrogesterone tablets, with over 90 products having passed national consistency evaluations. Additionally, the company has broadened its institutional market coverage by securing tender awards for 23 commercial drug products under China's National Centralized Volume-Based Procurement program while expanding strategic academic-industry research collaborations for oligonucleotide synthesis and specialized drug delivery systems.